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Pancreatic cancer is one of the most recalcitrant and lethal of all cancers.
We examined the effects of Anemarrhena asphodeloides (AA) and timosaponin-AIII (TAIII), a steroidal saponin present in AA, on pancreatic cancer
cell proliferation and aimed to elucidate their potential apoptotic mechanisms of action. Viability assays and cell cycle analysis revealed that both
AA and TAIII significantly inhibited pancreatic cancer cell proliferation
and cell cycle progression compared to treatment with gemcitabine, the
standard chemotherapeutic agent for advanced pancreatic cancer. We identified a dose-dependent increase in caspase-dependent apoptosis and activation of pro-apoptotic PI3K/Akt pathway proteins, with a subsequent
downregulation of pro-survival PI3K/Akt pathway proteins, in pancreatic
cancer cells treated with AA or TAIII over those treated with gemcitabine.

(Received 5 January 2018, revised 1 May
2018, accepted 18 May 2018)
doi:10.1002/2211-5463.12457

Pancreatic ductal adenocarcinoma (PDAC) is one of
the most lethal cancers with nearly equal incidence
and mortality rates due to a combination of factors
including a lack of early detection methods, limited
surgical options, and ineffective treatment options due
to drug and apoptotic resistance [1]. Surgery remains
the only potential curative therapeutic approach but is
not a viable option for most patients as more than
80% are already in an advanced disease state at the
time of detection [2]. Relapse of the disease is common
in patients whose tumors are initially resectable, rendering chemotherapy a necessity even after surgical
intervention. Standard chemotherapy for advanced
PDAC since 1997 has been the deoxycytidine analog

gemcitabine alone or in combination with nab-Paclitaxel or 5-fluorouracil [3]. However, the prognosis in
these patients remains poor due to chemoresistance
resulting in substantial treatment failure in addition to
debilitating side effects [4].
Mutations within a concerted network of several
core cellular signaling pathways can be found throughout the progression of PDAC [5]. Phosphatidylinositol-3 kinase (PI3K)/Akt signaling represents one of the
most frequently altered pathways in PDAC and regulates the activity of a litany of substrates involved in
cell survival, proliferation, growth, and motility.
Increased activity of the serine/threonine kinase Akt
promotes cell survival and evasion of apoptosis

Abbreviations
AA, Anemarrhena asphodeloides; BAD, Bcl2-associated agonist of cell death; GSK, glycogen synthase kinase; KRAS, Kirsten rat sarcoma
viral oncogene homologue; mTOR, mammalian target of rapamycin; PDAC, pancreatic ductal adenocarcinoma; PI3K, phosphatidylinositol-3
kinase; PTEN, phosphatase and tensin homologue deleted on chromosome ten; TAIII, timosaponin-AIII.
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through the inhibition of pro-apoptotic proteins
including Bcl-2-associated death promoter (BAD) and
the activation of pro-survival substrates and has been
observed in several types of cancers [6,7]. One of the
primary negative regulators of PI3K/Akt activity is
phosphatase and tensin homologue deleted on chromosome ten (PTEN); inactivating mutations within PTEN
contribute to the hyperactive state of the PI3K/Akt
pathway and progression of PDAC [8]. Glycogen synthase kinase-3 (GSK-3a/b) plays a critical role in controlling several cell cycle regulators and transcription
factors which affect cell fate. Akt catalyzes the inhibition of GSK-3 via phosphorylation at Ser21 and Ser9
(on GSK-3a and GSK-3b, respectively) [9]. The mammalian target of rapamycin (mTOR) signaling pathway
is also affected by mutational Akt activity through
phosphorylation and activation of the mTORC1 complex. Phosphorylated mTOR promotes cell growth by
enhancing the transcription of growth factor mRNA
via the activation of several substrates, including p70
S6 kinase 1 [10].
The exploration of plants as a source of chemotherapeutic agents in Western medicine has been active since
the 1950s with the discovery of the vinca alkaloids vinblastine and vincristine isolated from Catharanthus roseus
and
the
isolation
of
cytotoxic
podophyllotoxins [11]. The rhizome of Anemarrhena asphodeloides Bunge (AA) has been a significant
fixture in Traditional Chinese Medicine for thousands
of years and is the only species in the genus. Its primary chemical components are steroidal saponins, flavonoids, phenylpropanoids, alkaloids, steroids, organic
acids, and anthraquinones. Most abundant among the
identified constituents are steroidal saponins. Timosaponin-AIII (TAIII) , a steroidal saponin first isolated
from AA by Kawasaki et al. in 1963, has exhibited
pro-apoptotic and antimetastatic efficacy against nonsmall-cell lung cancer, melanoma, colorectal carcinoma, and breast cancer in vitro [12–16]. Although
recent studies suggest AA and its constituents may possess potent antitumor properties, its prospective use in
the treatment of refractory pancreatic cancer has yet to
be elucidated. In this study, we identified the inhibitory
effects of AA and TAIII on PDAC cell lines in part
through modulation of PI3K/Akt pathway proteins.

Materials and methods
Chemicals and reagents
Timosaponin-AIII (CAS registry number: 41059-79-4) was
purchased from Santa Cruz Biotechnology (Santa Cruz,
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CA, USA). HPLC analysis by the manufacturer determined
the purity was > 98%. Gemcitabine hydrochloride (CAS
registry number: 122111-03-9) was purchased from SigmaAldrich (St. Louis, MO, USA). HPLC analysis by the manufacturer determined a purity > 98%. Rabbit monoclonal
antibodies against cleaved caspase-3 (Asp175; Cat. 9664),
mouse monoclonal antibody against b-actin (Cat. 3700),
and horseradish peroxidase (HRP)-linked secondary antibodies were purchased from Cell Signaling Technology
(Beverly, MA, USA).

Preparation of AA extract and TAIII stock
Dried extract granules of AA Bunge rhizome were originally obtained from Tianjiang Pharmaceutical Co. (Jiangsu,
China. Batch number 1005417; corresponds to Chinese
Pharmacopeia specification) and kindly provided to us by
C. Zhang. The dried extract was reconstituted in sterile mQ
water at a ratio of 1 : 4 w/v and mixed on a rocker at
room temperature for 72 h. The solution was centrifuged at
2000 g for 10 min to separate undissolved particles and
sterilized using a 0.2 lm PEM filter. Total protein content
within the extract stock was determined using the Pierce
BCA protein assay (Thermo Fisher Scientific Inc., Waltham, MA, USA). Extract stock was stored at 4 °C and
diluted with sterile mQ water to the indicated concentration
prior to each experiment.
A stock solution of 8 mM TAIII was prepared in DMSO
then diluted with sterile mQ water to a final concentration
of 0.5% DMSO for each treatment condition. Stock solution was stored at 20 °C.

Determination of TAIII content in AA extract via
LC–MS–TOF
LC–MS analysis was performed using Agilent 1200 series/
6230 TOF liquid chromatography/mass spectrometer with
a SynergiTM 4 lm Hydro-RP LC column (250 9 4.6 mm)
 pore size. Samples of AA (0.5 mgmL 1) and
with 80 A
TAIII (0.1 mgmL 1) were run in positive mode at a flow
rate of 1 mL per min using a 14-min gradient of 0–98%
acetonitrile in 0.05% formic acid. TAIII content in the
AA extract was determined by comparison with reference
sample.

Cell culture
PANC-1 and BxPC-3 cells were cultured in growth medium
(Dulbecco’s modified Eagle’s medium with L-glutamine
and RPMI 1640 with L-glutamine, respectively) supplemented with 10% FBS and 1% penicillin–streptomycin
(100 unitsmL 1 penicillin and 100 lgmL 1 streptomycin).
Both PANC-1 and BxPC-3 cell lines were authenticated via
STR profiling (Promega, Madison, WI, USA) and
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confirmed to be an exact match to the indicated cell line by
ATCC (STR12699 and STR12675). Cells were maintained
in a humidified incubator in 5% CO2 at 37 °C.

Cell viability assay
Cell viability was assessed via modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay using the
CellTiter 96 Non-Radioactive cell proliferation assay (Promega). Briefly, cells were seeded at 10 000 cells per well in
a 96-well plate and allowed to attach overnight. The cells
were then treated with equal volumes of various concentrations of AA and TAIII, with and without 1 mM gemcitabine, 1 mM gemcitabine alone, and sterile mQ water or
0.5% DMSO vehicle control for 24 or 48 h. Absorbance
was measured as optical density (OD) at a wavelength of
570 nm using a VersaMax microplate reader (Molecular
Devices, LLC. Sunnyvale, CA, USA). The OD of vehicletreated control cells represented 100% viability. Viability of
treated cells was expressed as a percentage of vehicle-treated control cells.

Flow cytometric analysis of cell cycle distribution
Cell cycle distribution was determined using propidium
iodide (PI) cellular DNA staining. BxPC-3 cells were seeded
at a density of 1.25 9 106 cells in 5 mL in 25-cm2 flasks
and allowed to attach overnight. The media was then
replaced with fresh media containing each treatment condition. After 24 h, the cells were harvested and washed then
re-suspended in cold PBS. The cells were added dropwise
to cold 70% ethanol and fixed overnight at 20 °C. Fixed
cells were washed in cold PBS and filtered through a 40-lM
nylon cell strainer to remove aggregates. The cells were
stained at a density of 1 9 106 cells in 500 lL staining
solution (0.1% Triton X-100, 20 lgmL 1 PI, and
0.2 mgmL 1 DNase-free RNase A in PBS) and incubated
at RT in the dark for 30 min. Intracellular DNA data were
acquired by a BD Accuri C6 cytometer (Becton Dickinson,
San Jose, CA, USA). Debris and doublets were excluded
by gating on forward vs. side scatter-area and forward scatter-area vs. forward scatter-height. Gates were performed
on the control sample and uniformly applied to each sample. At least 10 000 gated events were used for analysis and
the resulting cell cycle distribution was determined using
FCS EXPRESS 6 software (De Novo Software, Glendale, CA,
USA).

Anemarrhena induces pancreatic cancer cell apoptosis

Scientific Inc.) was used to obtain whole cell lysate. The
samples were sonicated, and protein concentrations were
determined using the BCA Protein Assay. Equivalent protein content was loaded into each lane, separated by SDS/
PAGE (Mini-PROTEAN TGX Pre-Cast gels, 4–20%), and
transferred to PVDF membranes. Membranes were blocked
with 5% nonfat dry milk in Tris-buffered saline with
0.05% Tween-20 (TBST) and probed with primary antibodies against indicated proteins diluted in 5% nonfat dry milk
or BSA in TBST overnight at 4 °C. Blots were then incubated with a HRP-conjugated secondary antibody specific
to the primary antibody in 5% nonfat dry milk in TBST at
RT for 1 h. Signal was detected using SuperSignal West
Pico PLUS Chemiluminescent Substrate (Pierce, Rockford,
IL, USA). Blots were imaged and analyzed using the Amersham Imager 600 and the accompanying IMAGEQUANT TL
8.1 software (GE Healthcare Life Sciences, Pittsburgh, PA,
USA).

Analysis of PI3K/Akt pathway signaling activity
via bead-based multiplex assay
Phosphorylated forms of Akt (Ser473), mTOR (Ser2248),
BAD (Ser136), p70 S6 kinase (Thr389), GSK-3a/b (Ser21/
Ser9), and PTEN (Ser380) were detected in the lysate of
PANC-1 cells treated under the aforementioned conditions
using the Bio-Plex Pro cell signaling Akt panel (Bio-Rad,
Hercules, CA, USA). The only deviation from the given
protocol was the use of 19 Halt Protease Inhibitor Cocktail in place of phenylmethylsulfonyl fluoride in the cell
lysis buffer. Analysis was performed using the Luminex
MAGPIX (Luminex, Austin, TX, USA). Percent median
fluorescence intensity (MFI) of each analyte is expressed as
a percentage of the MFI corresponding to the vehicle control-treated sample.

Statistical analysis
Results presented as mean  SE of the number of indicated independent experiments. Statistical significance was
determined by performing a two-tailed, unpaired Student’s
t-test or one-way ANOVA followed by Tukey’s multiple
comparison post-test in GRAPHPAD PRISM 5.01 (GraphPad
Software, San Diego, CA, USA).

Results

Protein extraction and Western blot analysis

TAIII content in AA extract via LC–MS–TOF
analysis

PANC-1 cells were seeded at a density of 1.25 9 106 cells
in 5 mL in 25-cm2 flasks and treated as indicated above.
After collection, standard lysis buffer supplemented with
19 Halt Protease Inhibitor Cocktail (Thermo Fisher

As TAIII is one of the chemical signatures of AA, and
to relatively compare the activity of the whole extract
with TAIII as a single compound, we first wanted to
confirm the presence of TAIII in our AA extract. We
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employed LC–MS–TOF to compare the ESI-MS spectra of the extract (Fig. 1A; RT: 11.24) to that of the
TAIII reference standard (Fig. 1B; RT: 11.23). Analysis of the standard TAIII sample and the AA extract
showed the protonated molecule at m/z 741.44. Furthermore, fragment ions at m/z 579.38 [MH – Glu]+
and 417.34 [MH – Glu – Gal]+ characteristic of TAIII
are present in both ESI-MS spectra [17].
AA enhances inhibition of pancreatic cancer cells
by gemcitabine
PANC-1 and BxPC-3 cells are resistant to gemcitabine
to varying degrees, with PANC-1 cells exhibiting less
sensitivity than BxPC-3 cells [18]. To determine the
effect of AA alone and in the presence of gemcitabine
on the viability of pancreatic cancer cells, we treated
PANC-1 and BxPC-3 cells for 24 and 48 h with
increasing concentrations of AA or AA and 1 mM
gemcitabine. As shown in Fig. 2, AA exhibited a
dose-dependent decrease in viability of both cell lines.
The viability of PANC-1 cells exposed to 750, 1000,
and 1250 lgmL 1 AA alone and with gemcitabine
for 24 and 48 h was substantially decreased compared
to those treated with only gemcitabine (P < 0.001)
(Fig. 2A,B). Co-treatment of 1000 and 1250 lgmL 1
AA plus gemcitabine for 24 h was significantly more
effective at inhibiting viability than the same

C. B. MarElia et al.

concentration of AA alone (P < 0.05 or P < 0.01;
Fig. 2A). A marked decrease in cell proliferation
was seen in BxPC-3 cells treated with AA alone and
with gemcitabine at concentrations > 500 lgmL 1
(P < 0.05 or P < 0.001; Fig. 2C,D). BxPC-3 cells treated for 24 h with 500, 750, and 1000 lgmL 1 AA
plus gemcitabine exhibited significantly less viability
than those treated with the same concentration of AA
(P < 0.05 or P < 0.01). Taken together, these data
suggest that AA not only inhibits the viability of
PANC-1 and BxPC-3 cells, but it also appreciably
enhances the effect of gemcitabine in a dose-dependent manner.
Effects of TAIII on viability of pancreatic cancer
cell lines
We next wanted to examine the effect of the single
compound TAIII on the viability of PANC-1 and
BxPC-3 cells. As shown in Fig. 3, TAIII dose-dependently inhibited PANC-1 cells (Fig. 3A,B), with the
highest dose reducing the viability after 24 and 48 h to
~ 25% and 19%, respectively. Viability of PANC-1
cells treated for 24 h with 5, 10, and 20 lM TAIII was
significantly less than in those treated with gemcitabine
alone (P < 0.05 or P < 0.001). Simultaneous exposure
of TAIII with gemcitabine also resulted in significant
inhibition of PANC-1 cells compared to gemcitabine,

Fig. 1. TAIII present in AA extract. The presence of timosaponin-AIII in our AA extract was determined by comparing the LC–MS–TOF ESI
spectra of the whole extract (A) to that of the TAIII reference sample (B).
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Fig. 2. AA inhibits viability of PDAC cell
lines and potentiates gemcitabine efficacy.
PANC-1 (A,B) and BxPC-3 (C,D) cells were
incubated with the indicated
concentrations of AA, with and without
1 mM gemcitabine, 1 mM gemcitabine
alone, or vehicle for 24 (A,C) or 48 (B,D) h.
Data from three independent experiments
are expressed as mean  SE. Viability
was calculated as a percentage of the
vehicle-treated control cells. Statistically
significant inhibition was determined
compared to cells treated with
gemcitabine alone (*P < 0.05, **P < 0.01,
***P < 0.001) and between treatment
with AA alone and AA + gemcitabine
(#P < 0.05, ##P < 0.01).

Fig. 3. Effect of TAIII on PANC-1 and
BxPC-3 cell viability. PANC-1 (A,B) and
BxPC-3 (C,D) cells were incubated with
the indicated concentrations of TAIII, with
and without 1 mM gemcitabine, 1 mM
gemcitabine alone, or vehicle for 24 (A,C)
or 48 (B,D) h. Data from three
independent experiments are expressed
as mean  SE. Viability was calculated as
a percentage of the vehicle-treated control
cells. Statistically significant inhibition was
determined compared to cells treated with
gemcitabine alone (*P < 0.05, **P < 0.01,
***P < 0.001).

although not to the same degree as the TAIII-only
samples. BxPC-3 cells treated for 24 h with 10 and
20 lM TAIII alone and 10 lM TAIII with gemcitabine
also exhibited significantly reduced viability compared
to gemcitabine treatment (P < 0.05 or P < 0.01;
Fig. 3C). There was no significant difference observed
in BxPC-3 cells treated for 48 h with TAIII alone or
with gemcitabine compared to gemcitabine alone
(Fig. 3D).

BxPC-3 cell cycle progression is inhibited by AA
and arrested in G1 phase by TAIII
To elucidate the effect of AA and TAIII treatment on
the progression of the cell cycle, BxPC-3 cells treated
with increasing concentrations of either AA or TAIII
for 24 h were fixed and stained with PI and their
DNA content was analyzed by flow cytometry. As
shown in Fig. 4A, AA markedly disrupts the cell cycle.

FEBS Open Bio 8 (2018) 1155–1166 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
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A

B
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DMSO

250 µg • mL-1 AA

750 µg • mL-1 AA

1250 µg • mL-1 AA

DMSO

5 µM TAIII

10 µM TAIII

20 µM TAIII

Fig. 4. AA and TAIII induce cell cycle arrest and dysfunction in BxPC-3 cells. Flow cytometric analysis of BxPC-3 cells treated with the
indicated concentrations of AA (A), TAIII (B), or 0.5% DMSO for 24 h. Cell cycle distribution was determined by staining intracellular DNA
with PI. At least 10 000 gated cells used for analysis of each sample. Data shown are representative of three independent experiments.
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Fig. 5. Co-treatment with AA or TAIII enhances ability of gemcitabine to impede BxPC-3 cell cycle progression. Flow cytometric analysis of
BxPC-3 cells treated with the indicated concentrations of AA + 1 mM gemcitabine (A), TAIII + 1 mM gemcitabine (B), or 1 mM gemcitabine
alone for 24 h. Cell cycle distribution was determined by staining intracellular DNA with PI. At least 10 000 gated cells used for analysis of
each sample. Data shown are representative of three independent experiments.
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At 250 lgmL 1 AA, there is a greater population of
cells in G1 phase compared to the control sample
(73.90% and 47.17%, respectively), allowing fewer
cells to reach S and G2/M phases. At 750 and
1250 lgmL 1 AA, the cells exhibit a drastic shift in
the cycle resulting in a large portion of the cells stalling in the sub-G1 phase (37.68% and 78.90%, respectively) compared to the control (1.89%). Exposure to
increasing concentrations of TAIII for 24 h resulted in
a marked increase in the population of cells in G1
phase (50.06%, 72.92%, and 72.86%) and a subsequent decrease in the S and G2/M phase populations
compared to the control (Fig. 4B). Cells treated with
20 lM TAIII exhibit a notable increase in the sub-G1
population compared to the control group (9.29% and
1.89%, respectively).
AA and TAIII improve disruption of BxPC-3 cell
cycle by gemcitabine
Pancreatic cancer is frequently resistant to gemcitabine,
which can be due to several possible mechanisms
including efflux from the cell, downregulation of gemcitabine-activating proteins, and upregulation of gemcitabine-inactivating proteins [19]. We therefore wanted
to determine whether either AA or TAIII co-treatment
with gemcitabine could have a greater effect on cell
cycle progression than gemcitabine alone. Exposure to
AA and gemcitabine dramatically increased the portion
of cells in the sub-G1 phase when compared to gemcitabine alone (Fig. 5A). The co-treated cells also
resulted in a more dramatic shift from the G1 to subG1 populations than those treated with the corresponding concentration of AA alone (Fig. 4A). TAIII plus
gemcitabine resulted in a dose-dependent arrest in G1

Table 1. Percentage of total gated cells in each population.
Treatment

Sub-G1

G1

S

G2/M

DMSO
AA 250 lgmL 1
AA 750 lgmL 1
AA 1250 lgmL 1
TAIII 5 lM
TAIII 10 lM
TAIII 20 lM
Gemcitabine 1 mM
AA 250 lgmL 1 + 1 mM gem
AA 750 lgmL 1 + 1 mM gem
AA 1250 lgmL 1 + 1 mM gem
TAIII 5 lM + 1 mM gem
TAIII 5 lM + 1 mM gem
TAIII 5 lM + 1 mM gem

1.89
2.96
37.68
78.90
1.31
1.77
9.29
4.50
3.07
69.23
83.08
3.93
5.14
22.21

47.17
73.90
41.86
6.52
50.06
72.92
72.86
67.68
73.70
14.00
11.83
71.70
76.42
56.12

23.10
11.01
15.42
13.95
27.24
11.67
7.10
13.26
8.01
15.42
4.67
10.84
6.28
14.58

26.35
11.54
4.69
0.41
20.39
12.95
10.39
13.15
13.33
1.14
0.31
12.84
11.39
6.38

1162

phase and subsequent increase in the sub-G1 population compared to the gemcitabine-only treated cells
(Fig. 5B). As with AA, co-treatment with TAIII and
gemcitabine resulted in a greater population of cells in
the sub-G1 phase than those treated with TAIII alone
(Fig. 4B). Table 1 summarizes the data from Figs 4
and 5. These results indicate that co-treatment of AA
or TAIII and gemcitabine is more effective at inducing
BxPC-3 cell cycle arrest than treatment with AA,
TAIII, or gemcitabine as a single agent.
AA and TAIII modulate activation of PI3K/Akt
pathway members
To determine the effect of AA and TAIII on the activation of PI3K/Akt pathway proteins, PANC-1 cells
were treated for 24 h as described above and evaluated
for phosphorylated Akt pathway proteins using the
Bio-Plex pro cell signaling Akt panel. Activation via
phosphorylation of the pro-survival proteins mTOR
and p70 S6 kinase was significantly decreased in
PANC-1 cells treated with AA alone and with gemcitabine compared to those in which only gemcitabine
was administered (P < 0.001; Fig. 6D,E). Inhibitory
phosphorylation of the pro-apoptotic proteins PTEN
and BAD was also significantly decreased in PANC-1
cells treated with AA alone and in combination with
gemcitabine compared to cells treated with gemcitabine alone (P < 0.01 or P < 0.001; Fig. 6B,C).
While the differences in the expression levels of phosphorylated Akt, PTEN, mTOR, BAD, and GSK-3
between cells treated with AA and those treated with
AA in the presence of gemcitabine did not reach statistical significance, there is a clear stepwise and dosedependent decrease. This may indicate that even subtle
differences in the activity of these efficient proteins
result in a biological effect before reaching levels of
statistical consequence. In the instance of phosphorylated p70 S6 kinase, expression does not appear to differ between cells treated with AA alone and with AA
in the presence of gemcitabine. It is possible that AA
alters the expression of some cellular targets in such a
drastic manner that it eclipses any effect gemcitabine
may have had. Phosphorylation of BAD, mTOR, and
p70 S6 kinase was significantly decreased in cells treated with 20 lM TAIII alone and with gemcitabine
compared to gemcitabine alone (P < 0.05 or P < 0.01;
Fig. 6C–E). Similar to the effect seen between treatment with AA and with AA plus gemcitabine, the
levels of phosphorylated BAD between cells treated
with 20 lM TAIII with and without gemcitabine do
not differ statistically, although there may still be a
biologically significant variance. Additionally, there
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Fig. 6. AA and TAIII in the presence and absence of gemcitabine modulate the activity of Akt signaling pathway members. PANC-1 cells
were treated with 1 mM gemcitabine, AA or TAIII (250, 750, or 1250 lgmL 1 and 5, 10, or 20 lM, respectively) alone or with 1 mM
gemcitabine, or vehicle for 24 h. Phosphorylation of several Akt pathway members (A–F) was measured by the magnetic-based cell
signaling multiplex assay. Results from two independent experiments are expressed as the relative percent MFI compared to the vehicletreated control for each analyte. Significant differences from the gemcitabine-only treatment are indicated (*P < 0.05, **P < 0.01,
***P < 0.001).

may still be other causative proteins targeted by AA
and TAIII that we have yet to identify.
AA and TAIII induce caspase-dependent
apoptosis in PANC-1 cells
Based on the combined results of the viability, cell
cycle, and multiplex analysis, we suspected AA and
TAIII elicit a caspase-dependent apoptotic cascade. To
investigate this, the lysates of PANC-1 cells treated

with AA or TAIII alone and in the presence of gemcitabine were examined by Western blot analysis for
activated caspase-3. The results showed a clear dosedependent increase in active caspase-3 in PANC-1 cells
treated with AA compared to the vehicle-treated control cells and those treated with only gemcitabine
(Fig. 7). There is a similar trend in the cells treated
with increasing concentrations of TAIII, albeit to a
lesser degree. Interestingly, the level of active caspase-3
in the cells treated with TAIII is slightly greater than

FEBS Open Bio 8 (2018) 1155–1166 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
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in the cells treated with both TAIII and gemcitabine
which mirrors the cell viability data seen in Fig. 3;
again this suggests that the presence of gemcitabine
affects the activity of TAIII within the cells. These
results indicate that AA and TAIII initiate apoptosis
in PANC-1 cells via a caspase-dependent mechanism.

Discussion and conclusion
Pancreatic ductal adenocarcinoma is one of the most
highly lethal cancers, and its incidence rate is currently
on the rise. Due to a lack of sensitive and accurate
detection methods, a propensity for metastasis, and
nearly universal drug resistance, the 5-year survival
rate among patients whose tumors have disseminated
at the time of detection is among the lowest of any
cancer [1,20]. In the three decades since the landmark
study that led to gemcitabine as the primary
chemotherapeutic agent for PDAC, progress toward a
more effective and less toxic treatment has been scant.
Recent treatment regimens such as gemcitabine + nabPaclitaxel and 5-fluorouracil, leucovorin, irinotecan,
oxaliplatin (FOLFIRINOX) have offered only modest
improvements to overall survival or debilitating side
effects, and therefore, the dire need for effective treatment with low toxicity still remains [21,22].
In recent years, interest in natural products such as
herbal extracts as anticancer agents has gained significant traction as they offer a multitude of active compounds and the potential for significant reduction in
the toxicity associated with traditional chemotherapy.
The extract of AA Bunge and its bioactive compound
TAIII have demonstrated anticancer effects in a number of cancer types; however, neither has been investigated for efficacy against PDAC cell growth and
gemcitabine resistance which we have done in our present study. Our results demonstrate that AA and
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TAIII markedly inhibit the growth of PANC-1 and
BxPC-3 cells and induce caspase-dependent apoptosis
by modulating the activity of PI3K/Akt pathway proteins involved in cell cycle and proliferation. As seen
in Fig. 2, treatment of PANC-1 and BxPC-3 cells with
AA exhibits a hormetic-like, biphasic dose response
wherein there is a low-dose stimulatory effect and
subsequent inhibition with increasing doses. This
dose-response phenomenon frequently occurs across
biological models as low concentrations of a particular substance elicit a protective stress response within
the cells, while higher doses overwhelm normal repair
mechanisms and are able to affect the intended receptor or signaling pathway [23,24]. A similar biphasic
dose response can be seen in the results of our multiplex analysis examining the expression of phosphorylated Akt and PTEN (Fig. 6A,B). Notably, both AA
and TAIII exhibit a greater degree of inhibition in the
PANC-1 cells which harbor an activating G12D
Kirsten rat sarcoma viral oncogene homologue
(KRAS) mutation than in the BxPC-3 cells which
express wild-type KRAS [25]. The results also reveal
that PANC-1 cells subjected to TAIII with gemcitabine exhibit less inhibition and modulation of
PI3K/Akt pathway proteins than those treated with
TAIII alone. The opposite trend is true for AA,
where treatment with AA in the presence of gemcitabine is more effective than with AA alone. This
could indicate that one or more of the processes by
which these cells resist gemcitabine also, at least partially, affects TAIII. Several mechanisms of gemcitabine resistance have been demonstrated in PDAC
cells and tumors, including highly efficient efflux of
the drug due to increased expression of multidrugresistant and ATP-binding cassette transporters which
could potentially also affect levels of TAIII within the
cells [26,27].

Fig. 7. Caspase-3 activation in PANC-1 cells treated with AA or TAIII and gemcitabine. The expression of activated caspase-3 was examined
by Western blot analysis of PANC-1 cells treated with AA or TAIII, alone or in combination with 1 mM gemcitabine, 1 mM gemcitabine
alone, or vehicle. Expression of b-Actin used as a loading control. Data shown are representative of three independent experiments.
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Regulation of the cell cycle involves a delicate balance of several concerted processes whose disruption
is a hallmark of tumor proliferation and drug resistance. Thus, chemotherapeutic agents that can force
cancer cells into an arrested cell cycle and eventually
induce apoptosis are of great interest. Our results
show that AA causes the cells to steadily decrease S
and G2 phase populations, while the majority of cells
enter a sub-G1 phase. Treatment with TAIII leads to
a dose-dependent decrease in S and G2 phase populations and increased G1 populations, resulting in G1
arrest. Multiplex analysis also revealed that treatment
with AA led to a significant decrease in phosphorylated GSK-3a/b and, along with TAIII (20 lM), significantly reduced phosphorylation of p70 S6 kinase
in PANC-1 cells compared to treatment with gemcitabine. p70 S6 kinase is activated by phosphorylation
and one of its major functions is regulation of cell
growth, and it is required for progression through the
G1 phase [28]. GSK-3 is a critical downstream kinase
in the PI3K/Akt pathway and can be inhibited via
Akt-mediated phosphorylation at Ser21 (GSK-3a)
and Ser9 (GSK-3b) [9]. Under normal conditions,
GSK-3b regulates cyclin D1 turnover and subsequently the transition from G1 phase to S phase by
phosphorylation; however, the role of GSK-3a/b in
PDAC remains a topic of controversy as it has
demonstrated both tumor suppressor and oncogenic
effects [29]. The activities of GSK-3 are also highly
dependent upon whether it is located in the cytoplasm or nucleus [30]. Taken together, these data
indicate that AA and TAIII disrupt PDAC cell cycle
progression, are concordant with the viability assay
data shown in Figs 2 and 3, and suggest the possibility of distinct mechanisms of action between AA and
TAIII.
In addition to aberrant cell cycle and growth regulation, PDAC is highly adept at circumventing apoptosis
induction by both intracellular mechanisms and
chemotherapeutic agents. It has been repeatedly
demonstrated that overactivation of the PI3K/Akt
pathway contributes to proliferation and drug resistance in PDAC. Thus, this pathway is an attractive
target in the search for vulnerabilities within PDAC
cells to attenuate resistance and induce apoptosis. Our
results indicate that while the combined effect is not
synergistic, both AA and TAIII singularly and with
gemcitabine are able to inhibit the phosphorylation of
PI3K/Akt pathway proteins and promote apoptosis in
PDAC cells to a much greater extent than gemcitabine
alone.
In summary, the results of our study demonstrate
that AA Bunge and its constituent TAIII modulate the
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activity of PI3K/Akt pathway proteins and are potent
inhibitors of PDAC cell proliferation. These findings
demonstrate the importance of further investigation
into the potential antitumorigenic and gemcitabinesensitizing properties of AA and TAIII in treating
advanced pancreatic cancer.
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